Nicotinic Acetylcholine Receptor Subtype Alpha-9 Mediates Triple-Negative Breast Cancers Based on a Spontaneous

Li-Chi Huang1, Ching-Ling Lin1, Jia-Zheng Qiu2

  • 1Department of Endocrinology, Cathay General Hospital, Taipei, Taiwan.

Insights

Targeting alpha-9 nicotinic acetylcholine receptor (α9-nAChR) can reduce triple-negative breast cancer (TNBC) metastasis. Gene editing of α9-nAChR in metastatic TNBC cells significantly decreased their invasive properties, suggesting its potential as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) presents a poor prognosis and high risk of recurrence.
  • Targeted therapies for TNBC are currently lacking, necessitating the identification of novel therapeutic targets.
  • Metastasis is a critical factor in TNBC progression and mortality.

Purpose of the Study:

  • To identify targetable molecules for attenuating TNBC metastasis.
  • To investigate the role of alpha-9 nicotinic acetylcholine receptor (α9-nAChR) in TNBC progression.
  • To evaluate the therapeutic potential of targeting α9-nAChR in TNBC.

Main Methods:

  • Generation of highly metastatic TNBC cells (LM) using a serial spontaneous pulmonary metastasis animal model.
  • Gene expression analysis of primary and metastasized TNBC cells to identify key molecular players.
  • CRISPR/Cas9 gene editing to ablate α9-nAChR in metastatic TNBC cells (2LM-α9-nAChR-null).
  • In vitro and in vivo assessment of cell migration, invasion, and mesenchymal marker expression.

Main Results:

  • Mesenchymal-related genes and α9-nAChR expression were significantly upregulated in metastatic TNBC cells (LM), particularly in second-round lung metastases (2LM).
  • CRISPR/Cas9-mediated knockout of α9-nAChR in 2LM cells (2LM-α9-nAChR-null) significantly attenuated mesenchymal markers, migration, and invasion.
  • Gene sequencing and protein expression analyses confirmed the high efficiency of α9-nAChR gene editing.

Conclusions:

  • α9-nAChR expression is essential for mediating TNBC metastasis during cancer development.
  • Targeting α9-nAChR holds potential for developing novel therapeutic strategies against TNBC metastasis.
  • α9-nAChR may serve as a valuable biomarker for targeted therapy in clinical investigations of advanced breast cancer.

Related Concept Videos